Does Ultragenyx Pharmaceutical (NASDAQ:RARE) Have A Healthy Balance Sheet?

Simply Wall StJan 10 02:58

RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $77

Futu NewsJan 8 20:34 · Ratings

Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not

Seeking AlphaJan 8 00:17

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Zacks Jan 7 22:35

BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $83

Futu NewsJan 7 08:31 · Ratings

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 7 05:30